2-[2-nitro-5-[4-(3,4-dimethoxybenzoyl)piperazinyl]phenyl]-1,3-dioxolane | 113260-06-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-[2-nitro-5-[4-(3,4-dimethoxybenzoyl)piperazinyl]phenyl]-1,3-dioxolane
• 英文别名: (3,4-dimethoxyphenyl)-[4-[3-(1,3-dioxolan-2-yl)-4-nitrophenyl]piperazin-1-yl]methanone
• CAS: 113260-06-3
• 化学式: C₂₂H₂₅N₃O₇
• 分子量: 443.456
• InChiKey: UPTFNIZBSNXGPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  106
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  1-(3,4-dimethoxybenzoyl)-4-(3-formyl-4-nitrophenyl)piperazine 生成 2-[2-nitro-5-[4-(3,4-dimethoxybenzoyl)piperazinyl]phenyl]-1,3-dioxolane
  参考文献：
  名称：

  MEANWELL, NICHOLAS A.;WRIGHT, JOHN J.

  摘要：

  DOI：

文献信息

• 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for
  申请人：Bristol-Myers Company

  公开号：US04701459A1

  公开（公告）日：1987-10-20

  Novel series of 2,3-dihydro-2-oxo-1H-imidazo[4,5-b]quinolinyl amine derivatives of Formula ##STR1## wherein R.sub.1 is hydrogen, lower alkyl; R.sub.2 is hydrogen, lower alkyl, lower alkoxy, halogen; R.sub.3 is hydrogen, lower alkyl; R.sub.4 is hydrogen, lower alkyl, alkanoyl, phenylalkanoyl wherein phenyl is optionally substituted with halogen, lower alkyl, lower alkoxy; R.sub.3 and R.sub.4 are joined together to form morpholinyl, piperidinyl or pyrrolidinyl optionally substituted with --CO.sub.2 R.sub.5 or ##STR2## wherein R.sub.5 is hydrogen or lower alkyl, and R.sub.6 is hydrogen, lower alkyl, cycloalkyl; 4-R.sub.7 -piperazinyl wherein R.sub.7 is --CO.sub.2 R.sub.8 wherein R.sub.8 is lower alkyl, phenyl optionally substituted with up to 2 halogen, lower alkyl or lower alkoxy; phenylalkanoyl of 7 to 10 carbon wherein phenyl is unsubstituted or independently substituted with up to 2 halogen, lower alkyl, lower alkoxy. The compounds are cyclic AMP phosphodiesterase inhibitors and are particularly useful as inhibitors of blood platelet aggregation and/or as cardiotonic agents.

  化合物系列是2,3-二氢-2-氧代-1H-咪唑[4,5-b]喹啉基氨基衍生物，其化学式为##STR1##其中R.sub.1为氢，低碳基；R.sub.2为氢，低碳基，低氧代基，卤素；R.sub.3为氢，低碳基；R.sub.4为氢，低碳基，脂肪酰基，苯基脂肪酰基，其中苯基可选择性地用卤素，低碳基，低氧代基取代；R.sub.3和R.sub.4连接在一起形成吗啉基，哌啶基或吡咯烷基，可选择性地用--CO.sub.2 R.sub.5或##STR2##取代，其中R.sub.5为氢或低碳基，R.sub.6为氢，低碳基，环烷基；4-R.sub.7-哌嗪基，其中R.sub.7为--CO.sub.2 R.sub.8，其中R.sub.8为低碳基，苯基，可选择性地用最多2个卤素，低碳基或低氧代基取代；含有7到10个碳的苯基脂肪酰基，其中苯基未取代或独立取代最多2个卤素，低碳基，低氧代基。这些化合物是环磷酸腺苷磷酸二酯酶抑制剂，特别适用于抑制血小板聚集和/或作为心力衰竭药物。
• Aminoimidazoquinoline derivatives
  申请人：Bristol-Myers Squibb Company

  公开号：EP0252503A1

  公开（公告）日：1988-01-13

  Novel series of 2,3-dihydro-2-oxo-1H-imidazo­[4,5-b]quinolinyl amine derivatives of Formula wherein R₁ is hydrogen, lower alkyl; R₂ is hydrogen, lower alkyl, lower alkoxy, halogen; R₃ is hydrogen, lower alkyl; R₄ is hydrogen, lower alkyl, alkanoyl, phenylalkanoyl wherein phenyl is optionally substituted with halogen, lower alkyl, lower alkoxy; R₃ and R₄ are joined together to form morpholinyl, piperidinyl or pyrrolidinyl optionally substituted with -CO₂R₅ or -NR₅R₆ wherein R₅ is hydrogen or lower alkyl, and R₆ is hydrogen, lower alkyl, cycloalkyl; 4-R₇-piperazinyl wherein R₇ is -CO₂R₈ wherein R₈ is lower alkyl, phenyl optionally substituted with up to 2 halogen, lower alkyl or lower alkoxy; phenylalkanoyl of 7 to 10 carbon wherein phenyl is unsubstituted or independently substituted with up to 2 halogen, lower alkyl, lower alkoxy. The compounds are cyclic AMP phosphodiesterase inhibitors and are particularly useful as inhibitors of blood platelet aggregation and/or as cardiotonic agents.

  式中 2,3-二氢-2-氧代-1H-咪唑并[4,5-b]喹啉胺衍生物新系列 其中 R₁ 是氢、低级烷基；R₂ 是氢、低级烷基、低级烷氧基、卤素；R₃ 是氢、低级烷基；R₄ 是氢、低级烷基、烷酰基、苯基烷酰基，其中苯基可选择被卤素、低级烷基、低级烷氧基取代；R₃ 和 R₄ 连接在一起形成吗啉基、哌啶基或吡咯烷基，其中苯基可选择被 -CO₂R₅ 取代，或 -4-R₇-哌嗪基，其中 R₇ 是 -CO₂R₈ ，其中 R₈ 是低级烷基，苯基可选择被最多 2 个卤素、低级烷基或低级烷氧基取代；碳原子数为 7 至 10 的苯基烷酰基，其中苯基未被取代或独立地被最多 2 个卤素、低级烷基或低级烷氧基取代。这些化合物是环 AMP 磷酸二酯酶抑制剂，尤其可用作血小板聚集抑制剂和/或强心剂。
• US4701459A
  申请人：——

  公开号：US4701459A

  公开（公告）日：1987-10-20